Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15948731 | 1.00 | PDE4A (0.48) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL29502274 | 1.00 | PDE4A (0.48) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL29506762 | 1.00 | PDE4A (0.48) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL818364 | 1.00 | PDE4A (0.48) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL5919108 | 1.00 | PDE4A (0.48) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL29375023 | 1.00 | PDE4A (0.48) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL2937201 | 0.93 | PDE4A (0.58) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL9818719 | 0.93 | PDE4A (0.58) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL28085169 | 0.93 | PDE4A (0.58) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL11274065 | 0.91 | PDE4A (0.56) | PDE4ALMNAL3MBTL1TDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778580-B1 | SYNTHESIS OF FURANS FROM SUGARS VIA KETO INTERMEDIATES | BP CORP NORTH AMERICA INC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20090163442-A1 | TREATMENT OF CANCER WITH 2-DEOXYGALACTOSE | LANDAU BERNARD R | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163442-A1 | TREATMENT OF CANCER WITH 2-DEOXYGALACTOSE | ST6GAL1, B4GALT1, GALK1 | PDE4A 2045/4885LMNA 4077/4885L3MBTL1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.